🩸 Clotting & Advanced Cardiac Risk

What this panel can settle, and by what logic

Nine markers, and three of them genuinely refine a cardiovascular risk estimate beyond a standard lipid panel.

1. Lp(a) is the best value on the panel and you only ever buy it once. Concentration is around 90% genetically determined, so a single measurement stands for life Nurmohamed 2023, and a high value is an independent causal risk factor for atherosclerotic disease and aortic stenosis, and roughly one adult in five carries a raised value Kronenberg 2022 while almost none of them know it.
2. ApoB (Apolipoprotein B) counts the particles that actually do the damage. In large cohort data ApoB outperformed LDL particle number as a marker of cardiovascular risk Epstein 2025, and it is the number to act on when triglycerides make LDL-cholesterol unreliable.
3. High-sensitivity troponin is a prognostic marker in people with no symptoms, which is not what most buyers think it is. Across 154,052 participants, troponin was detectable in 80.0% of people and the top third carried a relative risk of 1.43 for cardiovascular disease against the bottom third Willeit 2017. That is a risk gradient, not a heart attack.
4. Fibrinogen Activity and Factor II Activity (Prothrombin) describe coagulability, and hs-CRP (High-Sensitivity C-Reactive Protein) arbitrates the rest of the panel by showing whether anything here is raised simply because you are inflamed.

What it cannot settle, and what would

D-Dimer does not belong on a screening panel, and a raised one here can start a chain of tests you did not need. It is a rule-out test that only works applied to somebody with symptoms and an assessed pretest probability: the age-adjusted cutoff study enrolled 3,346 patients with suspected pulmonary embolism, among whom the actual prevalence was 19% Righini 2014. In a well person the pretest probability is near zero, so a positive result is overwhelmingly a false alarm — and the next step it triggers is a CT pulmonary angiogram with contrast and radiation.

It cannot tell you whether you have a clotting disorder. Nothing here is a thrombophilia test, and the ASH 2023 guidelines are largely about restraining that testing rather than encouraging it Middeldorp 2023. Inherited thrombophilia is investigated after a clot, in selected people, by a clinician.

ADMA and SDMA, TMAO (Trimethylamine N-oxide) and Lp-PLA2 Activity have no treatment attached to them. TMAO is an interesting metabolite of gut-microbial choline and carnitine metabolism with an association to cardiovascular risk Gatarek 2021; Lp-PLA2 predicted events and then failed the test that matters, since darapladib cut its activity by 65% without improving outcomes Wallentin 2016. Paying to measure a number you cannot usefully move is the most avoidable spend on this page.

And it cannot see your arteries. A coronary artery calcium score reports plaque directly and adds predictive information beyond risk factors and even beyond a polygenic risk score Khan 2023. If the question is whether you have coronary disease, that scan answers it and this panel does not.

Draw conditions that decide whether the money is wasted

Two markers here are ruined by ordinary life, and they are the two most likely to frighten you.

1. Do not draw D-Dimer or High-Sensitivity Troponin T within a week of an illness, injury, surgery or a hard training block. Both rise non-specifically in all of those, and a raised D-dimer in that setting is uninterpretable rather than informative Righini 2014. A detectable troponin after a marathon is expected and is not a cardiac event Willeit 2017.
2. Fast 9 to 12 hours, and eat normally for the days before. TMAO (Trimethylamine N-oxide) responds to recent intake of red meat, eggs and fish, so a steak dinner produces a raised result that reflects last night rather than your metabolism Gatarek 2021.
3. Declare anticoagulants, and any estrogen. Warfarin lowers Factor II Activity (Prothrombin) activity by design and a direct oral anticoagulant interferes with several clotting assays; combined hormonal contraception and pregnancy both raise fibrinogen and D-dimer on their own.
4. Buy Lp(a) once and never repeat it. Ask which assay was used and in what units, since a result in nmol/L and one in mg/dL are not interchangeable Nurmohamed 2023.

How you would know it answered your question, and what each pattern means next

Five results. Two of them should change your treatment and two should change nothing.

• Lp(a) raised: never repeat it. What changes is everything else — a lower ApoB (Apolipoprotein B) target, blood pressure treated harder, and first-degree relatives told to measure theirs once Kronenberg 2022 Nurmohamed 2023.
• ApoB (Apolipoprotein B) above target: treat, then recheck at 8 to 12 weeks. That is roughly the interval over which a lipid-lowering change reaches steady state, and an earlier draw reads the transition Epstein 2025.
• D-Dimer raised with no symptoms: do not go straight to imaging. Repeat it once when you are well and take the result to a clinician who will assess pretest probability, which is the only context in which the number means anything Righini 2014.
• High-Sensitivity Troponin T detectable but within range: this is a risk signal, not an event Willeit 2017. It argues for a calcium score and tighter risk-factor control rather than for a repeat troponin Khan 2023.
• TMAO (Trimethylamine N-oxide), ADMA or Lp-PLA2 Activity raised in isolation: no action, and no retest. There is no intervention that improves outcomes by lowering them Wallentin 2016 Gatarek 2021.

Sources read for these sections

• Righini M, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014 · PMID 24643601
• Willeit P, et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. Journal of the American College of Cardiology 2017 · PMID 28750699
• Wallentin L, et al. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association 2016 · PMID 27329448
• Middeldorp S, et al. American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing. Blood Advances 2023 · PMID 37195076
• Nurmohamed NS, et al. Considerations for routinely testing for high lipoprotein(a). Current Opinion in Lipidology 2023 · PMID 35942815
• Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis. European Heart Journal 2022 · PMID 36036785
• Epstein E, et al. Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank. European Journal of Preventive Cardiology 2025 · PMID 40887080
• Gatarek P, et al. Trimethylamine N-oxide (TMAO) in human health. EXCLI Journal 2021 · PMID 33746664
• Khan SS, et al. Coronary Artery Calcium Score and Polygenic Risk Score for the Prediction of Coronary Heart Disease Events. JAMA 2023 · PMID 37219552